Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib and irinotecan in second-line small cell lung cancer
NCT05595889Phase 2
Key facts
- Status
- Unknown
- Start
- Dec 2022
- Primary completion
- Sep 2024
- Sponsor
- Fujian Medical University Cancer Hospital
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Drugs
- surufatinib
- Conditions
- small cell lung cancer (SCLC)
01
Overview
Phase 2, open-label trial of surufatinib in small cell lung cancer (SCLC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Progression-Free Survival at 100 months. Status: unknown.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Patients with histologically diagnosed small cell lung cancer who failed first-line standard therapy, with ECOG 0-1 and measurable lesions.
04
Endpoints
Primary
Progression-Free Survival
Beyond the preview
Go deeper on NCT05595889.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05595889.